Loading...
NPI 1154089993 · Arlington Heights, IL · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Universal Health Solutions Inc is a clinical medical laboratory provider located in Arlington Heights, Illinois. This profile covers 1 Medicare and 5 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Universal Health Solutions Inc |
| Address | 3455 W Salt Creek Ln Ste 400 |
| City | Arlington Heights |
| State | IL |
| ZIP | 60005 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | November 29, 2021 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $12.4M |
| Medicaid | $258.4K |
UNIVERSAL HEALTH SOLUTIONS INC is a Clinical Medical Laboratory based in ARLINGTON HEIGHTS, IL, with an NPI enumerated on 2021-11-29 (~5 years ago). Its reported billing profile and code mix align with a laboratory-focused operation rather than a clinical practice, reflecting a services model centered on diagnostic testing and specimen processing.
Medicare revenue is highly concentrated: total Medicare revenue reported is $12.4M and the precomputed top 3 Medicare codes account for 100.0% of that Medicare revenue. The entire Medicare book of business is driven by K1034 (1M claims, $12 avg paid/claim, $12.4M revenue), which alone represents 100.0% of Medicare revenue and ranks #44 of 30143 providers nationally (100th percentile; extreme outlier, far above typical national volume for this code).
Medicaid billing is much smaller in scale at $258.4K total, but also concentrated: the precomputed top 3 Medicaid codes account for 85.2% of Medicaid revenue. The Medicaid mix is led by U0003 ($130.4K, 50.5%), followed by 87811 ($49.9K, 19.3%) and U0005 ($39.9K, 15.4%), indicating Medicaid revenue is dominated by SARS‑CoV‑2 nucleic acid testing and immunoassay procedures.
The payer mix is effectively Medicare-dominant: reported Medicare revenue of $12.4M dwarfs Medicaid revenue of $258.4K, so the provider’s scale and financial exposure are overwhelmingly tied to Medicare-billed activity. From an analytic perspective this makes the organization single-payer dominant at scale, with Medicaid representing a modest supplemental revenue stream.
Code-level competitive standing differs sharply by payer. For Medicare K1034 the provider ranks #44 of 30143 providers nationally (100th percentile; extreme outlier), signaling national-level prominence for that single nonprescription self-test provision code; by contrast its Medicaid standing is typical to modest in-state — U0003 ranks #113 of 350 (68th percentile; typical, unremarkable volume), 87811 ranks #88 of 548 (84th percentile; typical, unremarkable volume), and U0005 ranks #78 of 210 (63th percentile; typical, unremarkable volume).
The clinical-service implications are clear from the code mix: K1034’s dominance on Medicare signals this entity is provisioning large volumes of FDA-authorized nonprescription self-administered COVID-19 tests, while the Medicaid footprint (U0003, U0005, 87811, and G2023) reflects conventional lab operations handling high-throughput NAAT processing, expedited NAAT services, immunoassay testing, and specimen collection. Together these codes imply centralized lab processing capacity and logistical workflows tailored to SARS‑CoV‑2 testing.
Concentration risk is material: dependence on K1034 for 100.0% of Medicare revenue and reliance on three codes for 85.2% of Medicaid revenue means revenue exposure is tightly tied to reimbursement and policy changes affecting those specific COVID‑19 testing codes. Analysts monitoring this profile should prioritize changes to K1034, U0003, and U0005 reimbursement rules or eligibility criteria when assessing near-term revenue continuity.
Given the NPI enumeration date of 2021-11-29 (~5 years ago) and the current reported volumes — particularly the 1M-claim activity for K1034 on Medicare — the data are consistent with rapid scaling in a narrowly focused COVID-19 testing service line since enumeration. This tenure plus an extreme outlier national rank for K1034 suggests the provider built substantial testing throughput capacity concentrated on nonprescription self-test provision and related laboratory processing.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
1 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 1,032,670 | $10 | $12.4M |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 1 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
1 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| K1034 | 17 | 1,150 | 720 | $10 | $414.9K |
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
5 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 1,790 | $70 | $130.4K |
| 87811 | The lab analyst performs the technical lab test to analyze for the presence of severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2) (Coronavirus disease [COVID–19]) in a specimen by… | 1,250 | $40 | $49.9K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 1,660 | $20 | $39.9K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1,550 | $20 | $35.6K |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 1,330 | $1 | $2.7K |
How this provider's Medicaid billing volume and revenue compare to other Illinois providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Illinois median
5 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 113 | 350 | 400 | $70 | $514.7K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 78 | 210 | 680 | $20 | $206.4K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 120 | 400 | 550 | $20 | $90.8K |
| 87811 | The lab analyst performs the technical lab test to analyze for the presence of severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2) (Coronavirus disease [COVID–19]) in a specimen by… | 88 | 550 | 240 | $40 | $42.4K |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 21 | 60 | 660 | $1 | $3.2K |
Other providers in the same ZIP code as Universal Health Solutions Inc, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Legacy Medical Care Inc | IL | Federally Qualified Health Center (FQHC) | $0 | $42.6M |
| A-z & Medical Supply Inc | IL | Durable Medical Equipment & Medical Supplies | $0 | $9.3M |
| Village Of Arlington Heights A | IL | Land Ambulance | $1M | $7.4M |
| Clearbrook | IL | Case Management Agency | $0 | $6.1M |
| Clarity Testing Services | IL | Clinical Medical Laboratory | $5.2M | $353.5K |
| Senad Osmanovic | IL | Ophthalmology Physician | $1.6M | $1.3M |
| Northwest Community Day Surgery Center Ii LLC | IL | Ambulatory Surgical Clinic/Center | $2.6M | $0 |
| Richard Siegel | IL | Hematology & Oncology Physician | $1.4M | $0 |
| Urszula Sobol | IL | Hematology & Oncology Physician | $1.2M | $12K |
| Randy Rich | IL | Hematology & Oncology Physician | $1.2M | $750 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.